Compare Mesoblast Limited (MESO) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Symbotic Inc — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Symbotic Inc trades at $42.63 (market cap $5.46B). The key difference: Symbotic Inc is far larger — about 3.1× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 1,965,805). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Symbotic Inc for 23 Days on average.
| MESO | SYM | |
|---|---|---|
Market Cap | $1.75B | $5.46B |
Volume | 239,027 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $20.96 | $87.30 |
52-Week Low | $13.19 | $38.22 |
Typical Hold Time | 15 Days | 23 Days |
Enterprise Value | $1.83B | $3.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
SYM trades at $42.63, down 1.57% today, with bearish technical signals dominating (15 sell vs 2 buy indicators). The stock shows mixed fundamentals with strong revenue growth projected ($2.6B in 2026) but negative 2025 net income of -$16.94M and thin 0.31% net margin. Recent earnings show two misses against expectations, though Q4 2025 beat estimates. Analyst consensus remains bullish with $60.33 price target despite technical weakness.
SYM presents a growth story with $22.5B backlog and expanding AI/robotics market positioning, but faces execution risks from customer concentration (85% Walmart revenue) and profitability challenges. The stock trades at premium valuations (P/E 1,051.5, EV/EBITDA 74.05) requiring significant future earnings growth to justify. Near-term support at $40-42 levels critical for maintaining current pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
